Physician profile
Marisel Bosques Rosado
NPI 1548253537
$246,744.70
in general payments reported to CMS, 2019-2025
9 companies · $46K in 2025
The $46K reported for 2025 was more than what 98% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25K · 2020: $6,560 · 2021: $15K · 2022: $35K · 2023: $51K · 2024: $67K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150K · Food and Beverage: $6,835 · Travel and Lodging: $5,928 · Consulting Fee: $1,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150,000.00 |
| Food and Beverage | $6,835.09 |
| Travel and Lodging | $5,928.13 |
| Consulting Fee | $1,390.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $146,156.51 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Gilead Sciences, INC. | $42,470.61 | 2019-2025 | Biktarvy, Sunlenca |
| Janssen Pharmaceuticals, INC | $25,154.11 | 2019-2024 | Symtuza |
| Theratechnologies INC. | $17,575.62 | 2019-2022 | |
| Janssen Products, Lp | $7,403.96 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $7,147.01 | 2019-2025 | Capvaxive, Pifeltro, Delstrigo |
| Janssen Scientific Affairs, LLC | $600.00 | 2021 | |
| Abbvie INC. | $139.13 | 2019-2023 | Mavyret |
| E.R. Squibb & Sons, L.L.C. | $97.75 | 2020-2024 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisel Bosques Rosado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.